David Martínez‐Cuadrón

2.0k total citations
56 papers, 537 citations indexed

About

David Martínez‐Cuadrón is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, David Martínez‐Cuadrón has authored 56 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 20 papers in Molecular Biology and 17 papers in Public Health, Environmental and Occupational Health. Recurrent topics in David Martínez‐Cuadrón's work include Acute Myeloid Leukemia Research (42 papers), Acute Lymphoblastic Leukemia research (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). David Martínez‐Cuadrón is often cited by papers focused on Acute Myeloid Leukemia Research (42 papers), Acute Lymphoblastic Leukemia research (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). David Martínez‐Cuadrón collaborates with scholars based in Spain, Chile and United States. David Martínez‐Cuadrón's co-authors include Pau Montesinos, Juan Eduardo Megías‐Vericat, Miguel Á. Sanz, José Luís Poveda, Salvador F. Aliño, María José Herrero, Rebeca Rodríguez‐Veiga, Blanca Boluda, Jaime Sanz and Virginia Bosó and has published in prestigious journals such as Blood, Cancer and British Journal of Haematology.

In The Last Decade

David Martínez‐Cuadrón

53 papers receiving 529 citations

Peers

Countries citing papers authored by David Martínez‐Cuadrón

Since Specialization

Citations

This map shows the geographic impact of David Martínez‐Cuadrón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Martínez‐Cuadrón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Martínez‐Cuadrón more than expected).

Fields of papers citing papers by David Martínez‐Cuadrón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Martínez‐Cuadrón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Martínez‐Cuadrón. The network helps show where David Martínez‐Cuadrón may publish in the future.

Co-authorship network of co-authors of David Martínez‐Cuadrón

This figure shows the co-authorship network connecting the top 25 collaborators of David Martínez‐Cuadrón. A scholar is included among the top collaborators of David Martínez‐Cuadrón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Martínez‐Cuadrón. David Martínez‐Cuadrón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? 2024 ·Annals of Hematology ·(unknown), Rebeca Rodríguez‐Veiga, David Martínez‐Cuadrón, Pau Montesinos	2
2	A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML) 2023 ·Blood ·Aintzane Zabaleta, Esperanza Martín‐Sánchez, (unknown), Peter Kim, Kamlesh Bisht, Hongfang Wang, (unknown), Tomáš Jelı́nek, (unknown), Felipe Prósper, Jesús F. San Miguel, David Martínez‐Cuadrón, Pau Montesinos, Bruno Paiva	1
3	Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study 2022 ·Cancers ·(unknown), Juan Eduardo Megías‐Vericat, (unknown), Blanca Boluda, Isabel Cano, (unknown), Rebeca Rodríguez‐Veiga, (unknown), Claudia Sargas, Miguel Á. Sanz, (unknown), Eduardo López Briz, José Luís Poveda, Javier de la Rubia, Pau Montesinos, David Martínez‐Cuadrón	2
4	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain 2021 ·European Journal Of Haematology ·(unknown), Blanca Boluda, Rebeca Rodríguez‐Veiga, Isabel Cano, (unknown), (unknown), Javier Marco, (unknown), (unknown), José Luís Piñana, Jaime Sanz, Amparo Sempere, José Cervera, Eva Barragán, Claudia Sargas, (unknown), Juan Eduardo Megías‐Vericat, David Martínez‐Cuadrón, Miguel Á. Sanz, Pau Montesinos	1
5	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control? 2020 ·Blood Reviews ·Juan Eduardo Megías‐Vericat, (unknown), Eva Barragán, David Martínez‐Cuadrón, Pau Montesinos	21
6	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia 2020 ·Annals of Hematology ·Juan Eduardo Megías‐Vericat, (unknown), (unknown), David Martínez‐Cuadrón, Pau Montesinos	34
7	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review 2018 ·Annals of Hematology ·Juan Eduardo Megías‐Vericat, David Martínez‐Cuadrón, Miguel Á. Sanz, Pau Montesinos	73
8	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain 2018 ·PharmacoEconomics - Open ·Blanca Boluda, Rebeca Rodríguez‐Veiga, David Martínez‐Cuadrón, Ignacio Lorenzo, Jaime Sanz, (unknown), Amparo Sempere, Leonor Senent, José Cervera, Pilar Solves, (unknown), (unknown), Miguel Á. Sanz, Pau Montesinos	3
9	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin 2017 ·Annals of Hematology ·(unknown), Rebeca Rodríguez‐Veiga, Begoña Igual, Pau Montesinos, Mar Tormo, (unknown), Mariano Linares, J.M. Fernandez-Alvarez, Antonio Salvador, (unknown), (unknown), Marisa Calabuig, (unknown), (unknown), Jaime Sanz, Guillermo Sanz, (unknown), Blanca Boluda, David Martínez‐Cuadrón, Miguel Á. Sanz	7
10	Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia 2017 ·Pharmacogenetics and Genomics ·Juan Eduardo Megías‐Vericat, Pau Montesinos, María José Herrero, Federico Moscardó, Virginia Bosó, David Martínez‐Cuadrón, José Luís Poveda, Miguel Á. Sanz, Salvador F. Aliño	2
11	A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia 2015 ·The Pharmacogenomics Journal ·Juan Eduardo Megías‐Vericat, María José Herrero, Luis Rojas, Pau Montesinos, Virginia Bosó, Federico Moscardó, David Martínez‐Cuadrón, José Luís Poveda, Miguel Á. Sanz, Salvador F. Aliño	9
12	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment 2015 ·Revista Iberoamericana de Micología ·Pau Montesinos, Rebeca Rodríguez‐Veiga, David Martínez‐Cuadrón, Blanca Boluda, (unknown), (unknown), Carmen Alonso, Jaime Sanz, (unknown), Guillermo Martı́n, (unknown), Guillermo Sanz, (unknown), Isabel Cano, Javier Palau, Ignacio Lorenzo, Isidro Jarque, Miguel Salavert, Paula Ramírez, Miguel Á. Sanz	5
13	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia 2015 ·Leukemia & lymphoma ·Pere Barba, Rodrigo Martino, David Martínez‐Cuadrón, (unknown), Albert Esquirol, (unknown), José González, Francesc Fernández‐Avilés, David Valcárcel, Ramón Guàrdia, Rafael F. Duarte, Jesús María Hernández‐Rivas, Eugènia Abella, Pau Montesinos, Josep‐María Ribera	3
14	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis 2015 ·Bone Marrow Transplantation ·Pau Montesinos, Rebeca Rodríguez‐Veiga, Blanca Boluda, David Martínez‐Cuadrón, (unknown), (unknown), Jaime Sanz, (unknown), (unknown), (unknown), Ignacio Lorenzo, Miguel Salavert, Javier Pemán, (unknown), Jesús Martı́nez, Nelly Carpio, Isidro Jarque, Guillermo Sanz, Miguel Á. Sanz	27
15	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients 2013 ·Annals of Hematology ·José Luís Piñana, Pau Montesinos, Rodrigo Martino, Lourdes Vázquez, Montserrat Rovira, Javier López, Montserrat Batlle, Á Figuera, Pere Barba, Juan José Lahuerta, Guillermo Debén, (unknown), Raimundo García, (unknown), Esperanza Lavilla, (unknown), David Martínez‐Cuadrón, Miguel Á. Sanz	32
16	WT1 isoform expression pattern in acute myeloid leukemia 2013 ·Leukemia Research ·Irene Luna, Esperanza Such, José Cervera, Eva Barragán, Mariam Ibáñez, Inés Gómez‐Seguí, Maria López‐Pavía, Marta Llop, Óscar Fuster, (unknown), Silvestre Oltra, Carmen Alonso, (unknown), Ignacio Lorenzo, David Martínez‐Cuadrón, Pau Montesinos, (unknown), Federico Moscardó, Pascual Bolufer, Miguel Á. Sanz	9
17	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients 2012 ·Annals of Hematology ·Irene Luna, Esperanza Such, José Cervera, Eva Barragán, Antonio Jiménez‐Velasco, (unknown), Mariam Ibáñez, Inés Gómez‐Seguí, Maria López‐Pavía, Marta Llop, Óscar Fuster, Silvestre Oltra, Federico Moscardó, David Martínez‐Cuadrón, (unknown), (unknown), Pau Montesinos, Guillermo Martı́n, Pascual Bolufer, Miguel Á. Sanz	6
18	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting 2012 ·Journal of Molecular Diagnostics ·Mariam Ibáñez, Esperanza Such, José Cervera, Irene Luna, Inés Gómez‐Seguí, Maria López‐Pavía, (unknown), Eva Barragán, Óscar Fuster, Marta Llop, Rebeca Rodríguez‐Veiga, (unknown), Silvestre Oltra, (unknown), Federico Moscardó, Pau Montesinos, David Martínez‐Cuadrón, Guillermo Martı́n, Miguel Á. Sanz	14
19	Central nervous system involvement at first relapse in patients with acute myeloid leukemia 2011 ·Haematologica ·David Martínez‐Cuadrón, Pau Montesinos, (unknown), (unknown), Lourdes Cordón, Rebeca Rodríguez‐Veiga, Guillermo Martı́n, Jaime Sanz, Jesús Martı́nez, Miguel Á. Sanz	19
20	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine‐based chemotherapy in patients with de novo acute myeloid leukemia 2011 ·Cancer ·David Valcárcel, Pau Montesinos, Isabel Sánchez‐Ortega, Salut Brunet, Jordi Esteve, David Martínez‐Cuadrón, Josep‐María Ribera, Mar Tormo, Javier Bueno, Rafael F. Duarte, (unknown), (unknown), Ramón Guàrdia, Miguel Á. Sanz, Jorge Sierra, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact